NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment-naïve subjects

Journal of Viral Hepatitis
L L VidalA F Santos

Abstract

Hepatitis C virus (HCV) NS3 protease inhibitors have been primarily designed against genotype 1, the one with the lowest response to dual therapy. However, less evidence of their efficacy on non-1 genotypes is available, and any such information is mostly concentrated on genotypes 2-4. This study evaluated HCV protease resistance profiles in the major six HCV genotypes and identified genetic barrier (GB) profiles to each available protease inhibitor across HCV strains from different locations worldwide. We obtained 15 099 HCV sequences from treatment-naïve subjects retrieved at the Los Alamos HCV Sequence Database. The wild-type codons of different HCV genotypes were used to analyse the smallest number of nucleotide substitution steps required for changing that codon to the closest one associated with drug resistance. The 36L and 175L RAVs were found as genetic signatures of genotypes 2-5, while the 80K RAV was found in all genotype 5 sequences. Genotypes 4 and 6 showed a higher GB to RAV mutations conferring resistance to telaprevir, while genotypes 2-5 presented baseline resistance to that drug, carrying the 36L mutation. Genotype 4 had a higher GB to simeprevir resistance, requiring three substitutions to acquire the 155K mu...Continue Reading

References

Jul 7, 2001·The New England Journal of Medicine·G M Lauer, B D Walker
Jan 17, 2002·The New England Journal of Medicine·D J Wyler
Mar 17, 2006·Journal of Acquired Immune Deficiency Syndromes : JAIDS·David A van de VijverCharles A B Boucher
Apr 15, 2006·International Journal of Medical Sciences·Stephen L Chen, Timothy R Morgan
Mar 6, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Silvana GaudieriMichaela Lucas
Sep 30, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Simone SusserChristoph Sarrazin
Feb 24, 2010·Antimicrobial Agents and Chemotherapy·Oliver LenzKenneth A Simmen
Nov 19, 2010·Proceedings of the National Academy of Sciences of the United States of America·Keith P RomanoCelia A Schiffer
Feb 3, 2011·Journal of Hepatology·Philippe Halfon, Stephen Locarnini
Apr 1, 2011·The New England Journal of Medicine·Fred PoordadUNKNOWN SPRINT-2 Investigators
Apr 1, 2011·The New England Journal of Medicine·Bruce R BaconUNKNOWN HCV RESPOND-2 Investigators
Jun 24, 2011·The New England Journal of Medicine·Ira M JacobsonUNKNOWN ADVANCE Study Team
Jun 24, 2011·The New England Journal of Medicine·Stefan ZeuzemUNKNOWN REALIZE Study Team
Sep 20, 2011·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·Simone SusserChristoph Sarrazin
Oct 26, 2011·Antimicrobial Agents and Chemotherapy·Lisette LagacéGeorge Kukolj
Dec 3, 2011·Proceedings of the National Academy of Sciences of the United States of America·Megan H PowdrillMatthias Götte
Jan 11, 2012·Liver International : Official Journal of the International Association for the Study of the Liver·G EsmatM E Gamil
Jan 19, 2012·Antimicrobial Agents and Chemotherapy·Christoph WelschIris Antes
Feb 4, 2012·Journal of Hepatology·Christoph SarrazinJean-Michel Pawlotsky
Apr 18, 2012·Antimicrobial Agents and Chemotherapy·Fiona McPheeClaudio Pasquinelli
Oct 23, 2012·Infectious Disease Clinics of North America·David L Wyles
Jan 11, 2013·Liver International : Official Journal of the International Association for the Study of the Liver·Virginia C ClarkDavid R Nelson
Apr 12, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·James C SullivanTara L Kieffer
Jun 27, 2013·The Journal of Infectious Diseases·Yves BenhamouMaria Beumont
Dec 3, 2014·Antimicrobial Agents and Chemotherapy·Tami Pilot-MatiasChristine Collins
Feb 15, 2015·British Medical Bulletin·Matthew D Sadler, Samuel S Lee

❮ Previous
Next ❯

Citations

Sep 30, 2016·PloS One·María Ángeles Jimenez-SousaSalvador Resino
Nov 6, 2018·World Journal of Hepatology·Monjur Ahmed

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.